株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

EpiCast Report:過敏性腸症候群(IBS)の疫学予測

EpiCast Report: Irritable Bowel Syndrome - Epidemiology Forecast to 2026

発行 GlobalData 商品コード 317757
出版日 ページ情報 英文 37 Pages
即納可能
価格
本日の銀行送金レート: 1USD=108.01円で換算しております。
Back to Top
EpiCast Report:過敏性腸症候群(IBS)の疫学予測 EpiCast Report: Irritable Bowel Syndrome - Epidemiology Forecast to 2026
出版日: 2017年11月01日 ページ情報: 英文 37 Pages
概要

過敏性腸症候群(IBS)は、腹部の不快感や痛み、膨満感、排便習慣の変化を特徴とする、慢性で再発する胃腸障害です。世界の主要7ヶ国(米国、フランス、ドイツ、イタリア、スペイン、英国、日本)で過敏性腸症候群(IBS)と診断された患者数は、2013年の4,077万人から、今後10年間で4,236万人まで、3.9%増加すると予測されています。

当レポートでは、世界の主要7ヶ国における過敏性腸症候群(IBS)について調査分析し、疾患の背景、危険因子と併存疾患、世界の動向、疫学予測などについて、体系的な情報を提供しています。

第1章 目次

第2章 イントロダクション

第3章 疫学

  • 疾患の背景
  • 危険因子と併存疾患
  • 世界の動向
    • 米国
    • EU5ヶ国
    • 日本
  • 予測手法
    • 利用した情報源
    • 利用しなかった情報源
    • 予測の前提条件と手法 - IBSの総患者数
    • 予測の前提条件と手法 - IBSのサブタイプ区分
  • IBSの疫学予測
    • IBSの総患者数
    • IBSの総患者数(年齢別)
    • IBSの総患者数(性別)
    • IBSの総患者数(年齢標準化)
    • IBSの総患者数(臨床サブタイプ別)
  • 議論
    • 疫学予測に関する考察
    • 分析の限界
    • 分析の強み

第4章 付録

図表

目次
Product Code: GDHCER167-17

Irritable bowel syndrome (IBS) is a chronic, relapsing gastrointestinal (GI) disorder that is characterized by abdominal discomfort or pain, bloating, and changes in bowel habit. Due to the lack of a demonstrable structural abnormality to explain these symptoms, IBS is classified as a functional GI disorder. IBS is sub-classified according to the predominant bowel habits. These sub-classifications are constipation-predominant IBS (IBS-C), diarrhea-predominant IBS (IBS-D), mixed-presentation IBS (IBS-M), and unsubtyped IBS (IBS-U).

In the 7MM, the diagnosed prevalent cases of IBS will increase from about 24 million cases in 2016 to around 25 million cases in 2026, at an Annual Growth Rate (AGR) of about 0.3% per year. In the five major European markets (5EU: France, Germany, Italy, Spain, and UK), the diagnosed prevalent cases of IBS will increase from around 9 million cases in 2016 to about 9.3 million cases in 2026, at an AGR of around 0.2%.

Italy had the highest age-standardized diagnosed prevalence of IBS in both men (almost 5%) and women (around 10%) in the 7MM. Spain had the lowest age-standardized diagnosed prevalence of IBS in men (nearly 0.9%) and women (around 2%). The difference in the age-standardized diagnosed prevalence of IBS between men and women was the highest in Italy, atover 5% greater in women than in men. Germany had the lowest difference in the age-standardized prevalence of IBS between men and women, at almost 0.8%.

The report "EpiCast Report: Irritable Bowel Syndrome - Epidemiology Forecast to 2026", provides an overview of the risk factors, comorbidities, and global trends for IBS in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast for the total prevalent cases of IBS. This report also includes a 10-year epidemiological forecast for the diagnosed prevalent cases of IBS segmented by age (18 years and older), sex, and clinical subtypes of predominant bowel habits (diarrhea-predominant IBS [IBS-D], constipation-predominant IBS [IBS-C], and mixed-presentation IBS [IBS-M]) in these markets.

Scope

  • The Irritable bowel syndrome (IBS) EpiCast Report provides an overview of the risk factors and global trends of IBS in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
  • It includes a 10-year epidemiological forecast for the total and the diagnosed prevalent cases of IBS. Diagnosed prevalent cases are segmented by age (18 years and older), sex, and clinical subtypes of predominant bowel habits (diarrhea-predominant IBS [IBS-D], constipation-predominant IBS [IBS-C], and mixed-presentation IBS [IBS-M]), and comorbid conditions (anxiety and depression).
  • The IBS epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy

The IBS EpiCast report will allow you to -

  • Develop business strategies by understanding the trends shaping and driving the global IBS market.
  • Quantify patient populations in the global IBS market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for IBS therapeutics in each of the markets covered.
  • Understand magnitude of IBS population by disease type and comorbidities.

Table of Contents

1 Table of Contents

1 Table of Contents 2

  • 1.1 List of Tables 3
  • 1.2 List of Figures 3

2 Irritable Bowel Syndrome: Executive Summary 4

  • 2.1 Related Reports 5
  • 2.2 Upcoming Related Reports 6

3 Epidemiology 7

  • 3.1 Disease Background 7
  • 3.2 Risk Factors and Comorbidities 8
  • 3.3 Global and Historical Trends 9
    • 3.3.1 US 11
    • 3.3.2 5EU 12
    • 3.3.3 Japan 12
  • 3.4 Forecast Methodology 13
    • 3.4.1 Sources 13
    • 3.4.2 Forecast Assumptions and Methods 17
  • 3.5 Epidemiological Forecast for IBS (2016-2026) 23
    • 3.5.1 Total Prevalent Cases of IBS 23
    • 3.5.2 Diagnosed Prevalent Cases of IBS 24
    • 3.5.3 Age-Specific Diagnosed Prevalent Cases of IBS 24
    • 3.5.4 Sex-Specific Diagnosed Prevalent Cases of IBS 25
    • 3.5.5 Diagnosed Prevalent Cases of IBS by Clinical Subtypes 26
    • 3.5.6 Diagnosed Prevalent Cases of IBS Subtypes with Comorbidity 27
  • 3.6 Discussion 28
    • 3.6.1 Epidemiological Forecast Insight 28
    • 3.6.2 Limitations of the Analysis 29
    • 3.6.3 Strengths of the Analysis 30

4 Appendix 31

  • 4.1 Bibliography 31
  • 4.2 About the Authors 35
    • 4.2.1 Epidemiologist 35
    • 4.2.2 Reviewers 35
    • 4.2.3 Global Director of Therapy Analysis and Epidemiology 36
    • 4.2.4 Global Head and EVP of Healthcare Operations and Strategy 36
  • 4.3 About GlobalData 37
  • 4.4 Contact Us 37
  • 4.5 Disclaimer 37

List of Tables

1.1 List of Tables

  • Table 1: Risk Factors and Comorbidities for IBS 8
  • Table 2: Comparison of the IBS Diagnostic Criteria Used in Epidemiological Studies 10
  • Table 3: 7MM, Total Prevalent Cases of IBS, Both Sexes, Ages ≥18 Years, N, Selected Years from 2016-2026 23
  • Table 4: 7MM, Diagnosed Prevalent Cases of IBS, Both Sexes, Ages ≥18 Years, N, Selected Years from 2016-2026 24
  • Table 5: 7MM, Diagnosed Prevalent Cases of IBS by Clinical Subtypes, Both Sexes, Ages ≥18 Years, N, 2016 27
  • Table 6: 7MM, Diagnosed Prevalent Cases of IBS Subtypes with Comorbidity, Both Sexes, Ages ≥18 Years, N, 2016 28

List of Figures

1.2 List of Figures

  • Figure 1: 7MM, Diagnosed Prevalent Cases of IBS, Both Sexes, Ages ≥18 Years, 2016 and 2026 5
  • Figure 2: 7MM, Age-Standardized Diagnosed Prevalence of IBS, Ages ≥18 Years, 2016 11
  • Figure 3: 7MM, Sources Used and Not Used, Total Prevalent Cases of IBS 13
  • Figure 4: 7MM, Sources Used, Diagnosed Prevalent Cases of IBS 14
  • Figure 5: 7MM, Sources Used , Diagnosed Prevalent Cases of IBS Clinical Subtypes 15
  • Figure 6: 7MM, Sources Used , Diagnosed Prevalent Cases of IBS With Comorbidity 16
  • Figure 7: 7MM, Age-Specific Diagnosed Prevalent Cases of IBS, Both Sexes, Ages ≥18 Years, N, 2016 25
  • Figure 8: 7MM, Sex-Specific Diagnosed Prevalent Cases of IBS, Both Sexes, Ages ≥18 Years, N, 2016 26
Back to Top